Biotech M&A – 2018 Deals

Biotech M&A With a Strong Start in 2018: More Deals to Follow?

Date Acquirer co. Acquirer ticker Acquired co. Acquired ticker Deal value Price/Share CVR (if any) Notes
01/05/2018 Takeda TKPYY TiGenix G9U.BR $626M 1.78 euro Belgian Co.
01/07/2018 Celgen CELG Impact Biomedicines Private $1.1B $7B milestones
01/22/2018 Sanofi SNY Bioverativ BIVV $11.6B $105 Belgian Co.
01/22/2018 Celgen CELG Juno JUNO $9B $87
1/29/2018 Sanofi SNY Ablynx NV ABLX $4.8B $55.61 Outbid Novo Nordisk
01/29/2018 Varian Medical Systems VAR Sirtex SRX.AX $1.28B $28 Australian Co.
02/13/2018 Astellas Pharma ALPMY Universal Cells Private $102.5M milestones to acquire 100% ownership
02/21/2018 Merck MRK Viralytics VLA.AX $394M Au$1.75 Australian Co.
04/09/2018 Novartis NVS AveXis AVXS $8.7B $218 SMA GeneTherapy
04/11/2018 Alexion ALXN Wilson Therapeutics WTX.ST $855M $27.93 Stockholm, Sweden,
04/26/2018 Endo International ENDP Somerset Therapeutics Private $190M sterile injectable and ophthalmic drugs
04/30/2018 United Therapeutics UTHR SteadyMed Ltd. STDY $216M $4.46 additional $2.63/ share upon the achievement of a milestone related to the commercialization of Trevyent®. The transaction, including the $75 million in contingent consideration, is valued at $216 million.
05/10/2018 Eli Lilly LLY ARMO BioSciences ARMO $1.6B $50
10/11/2018 Gurnet Point Capital Private Co. Corium International CORI $504M $12.5 CVR of $0.50 per share
10/18/2018 Novartis NVS Endocyte ECYT $2.1B $24
12/03/2018 GlaxoSmithKline GSK Tesaro TSRO $5.1B $75